Enrico Pesenti
Institute of Oncology Research(CH)
Publications by Year
Research Areas
Microtubule and mitosis dynamics, Cancer-related Molecular Pathways, Cancer therapeutics and mechanisms, Computational Drug Discovery Methods, Cancer, Hypoxia, and Metabolism
Most-Cited Works
- → Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents(2004)489 cited
- → Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications(2016)312 cited
- → Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor(2016)295 cited
- Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer.(2003)
- → PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer(2007)240 cited
- → A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity(2008)213 cited
- → Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 Kinase(2010)199 cited
- → 1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazoles: Identification of a Potent Aurora Kinase Inhibitor with a Favorable Antitumor Kinase Inhibition Profile(2006)190 cited
- → Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I(2008)165 cited
- → PHA-680632, a Novel Aurora Kinase Inhibitor with Potent Antitumoral Activity(2006)161 cited